PL345507A1 - Pharmaceutical uses of nab1 and nab2 - Google Patents

Pharmaceutical uses of nab1 and nab2

Info

Publication number
PL345507A1
PL345507A1 PL99345507A PL34550799A PL345507A1 PL 345507 A1 PL345507 A1 PL 345507A1 PL 99345507 A PL99345507 A PL 99345507A PL 34550799 A PL34550799 A PL 34550799A PL 345507 A1 PL345507 A1 PL 345507A1
Authority
PL
Poland
Prior art keywords
nab1
nab2
pharmaceutical uses
pharmaceutical
Prior art date
Application number
PL99345507A
Other languages
English (en)
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL345507A1 publication Critical patent/PL345507A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL99345507A 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2 PL345507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Publications (1)

Publication Number Publication Date
PL345507A1 true PL345507A1 (en) 2001-12-17

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99345507A PL345507A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Country Status (22)

Country Link
EP (1) EP1097200A1 (is)
JP (1) JP2002520020A (is)
KR (1) KR20010071832A (is)
CN (1) CN1317045A (is)
AP (1) AP2001002038A0 (is)
AU (1) AU763713B2 (is)
BR (1) BR9912018A (is)
CA (1) CA2336805A1 (is)
EA (1) EA200100028A1 (is)
EE (1) EE200100020A (is)
HR (1) HRP20010025A2 (is)
HU (1) HUP0102835A3 (is)
ID (1) ID27742A (is)
IL (1) IL140533A0 (is)
IS (1) IS5788A (is)
NO (1) NO20010166L (is)
NZ (1) NZ509174A (is)
PL (1) PL345507A1 (is)
SK (1) SK382001A3 (is)
TR (1) TR200100622T2 (is)
WO (1) WO2000003014A1 (is)
YU (1) YU1901A (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
AP2001002038A0 (en) 2001-03-31
TR200100622T2 (tr) 2001-10-22
EE200100020A (et) 2002-06-17
CA2336805A1 (en) 2000-01-20
BR9912018A (pt) 2006-01-31
IS5788A (is) 2000-12-22
AU763713B2 (en) 2003-07-31
EP1097200A1 (en) 2001-05-09
AU4791499A (en) 2000-02-01
NO20010166L (no) 2001-03-06
YU1901A (sh) 2005-06-10
HRP20010025A2 (en) 2001-12-31
NO20010166D0 (no) 2001-01-10
IL140533A0 (en) 2002-02-10
HUP0102835A2 (hu) 2001-11-28
SK382001A3 (en) 2001-09-11
NZ509174A (en) 2003-08-29
HUP0102835A3 (en) 2003-09-29
CN1317045A (zh) 2001-10-10
WO2000003014A1 (en) 2000-01-20
ID27742A (id) 2001-04-26
KR20010071832A (ko) 2001-07-31
EA200100028A1 (ru) 2001-08-27
JP2002520020A (ja) 2002-07-09

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
HUP9901454A3 (en) Dosage form of ibuprofen
AU8127998A (en) Quinoline compounds and medicinal uses thereof
GB9702202D0 (en) Diagnosis of arthritic conditions
HUP0000729A3 (en) Novel amide compounds and drugs containing the same
HUP0100184A3 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds and pharmaceuticals comprising them
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
PL347542A1 (en) Therapeutic product and its use
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
HUP0102835A3 (en) Pharmaceutical uses of nab1 and nab2
AU6866700A (en) Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
AU4107797A (en) Compounds for the treatment and prevention of diabetes
HK1035207A (en) Pharmaceutical uses of nab1 and nab2
GB9817348D0 (en) Pharmaceutical use of esters
AU5343498A (en) Thiophene compounds and medicinal use thereof
AU8561998A (en) Cyclic compounds and medicinal use thereof
AU1798100A (en) Use of peptide
GB2329335B (en) Medicament
HUP0004274A3 (en) Bispyrido-cycloheptane compounds and pharmaceutical compositions thereof
PL328978A1 (en) Suck tablets of antibacterial and anti-inflammatory therapeutic effect
GB9828707D0 (en) Pharmaceutical uses
GB2356257B (en) The manufacture and application of matched electrodes
GB9812758D0 (en) Proteasomal destruction of mRNA
GB9805125D0 (en) Medicament and assay
IL127227A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)